LSKL TFA

Description: LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.

Formula: C23H43F3N6O7

Molecular Weight: 572,62

References: Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543.

• Artikelnummer: TGMTP2147-1mg
• Hersteller: TargetMol Chemicals
• Hersteller Artikelnummer: TP2147-1mg
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK